Association Between Immune And Tumor Gene Signatures With Response Or Resistance To Tislelizumab Monotherapy Or In Combination With Chemotherapy In Gastroesophageal Adenocarcinoma.
JOURNAL OF CLINICAL ONCOLOGY（2020）
Abstract
3115Background: Tislelizumab, an anti-PD-1 monoclonal antibody, has demonstrated clinical benefit as a single agent and in combination with chemotherapy for patients (pts) with gastroesophageal ade...
MoreTranslated text
Key words
tislelizumab monotherapy,tumor gene signatures,gastroesophageal adenocarcinoma,chemotherapy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined